메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한정신약물학회 Clinical Psychopharmacology and Neuroscience Clinical Psychopharmacology and Neuroscience 제7권 제2호
발행연도
2009.1
수록면
44 - 50 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objective:Clozapine is the treatment of choice for treatment-resistant schizophrenia. However, some patients with clozapine treatment at the typical recommended dosage (300-600 mg/day) continue to experience significant symptoms. This naturalistic follow-up study evaluated the efficacy and safety of clozapine at a higher than typical dose in patients with refractory schizophrenia. Methods:Thirteen of 19 subjects with refractory schizophrenia completed this prospective, open-label trial. The primary efficacy measure was the Positive and Negative Syndrome Scale for Schizophrenia (PANSS), and safety measures included the Simpson Angus Rating Scale (SAS) and recording of adverse events. Repeated measures ANOVA was used to evaluate whether a higher dose of clozapine resulted in further symptom improvement. Results:No improvement was found in overall psychopathology, except for PANSS general psychopathology scores, when going from 600 mg/day to the higher dose of clozapine, although the higher dose was well tolerated. Conclusions:This open study suggests that clozapine at a higher dosage does not improve overall symptoms more than 600 mg/day, although has comparable tolerability. Augmentation or determination of other possible factors related to refractoriness should be considered to improve symptoms in cases in which typical dosage clozapine does not fully elicit a response. The results of this study must be confirmed with a larger sample size and controlled trials in the near future.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0